Stay updated with breaking news from Completes Enrollment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited...
/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...
Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P...
Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales
Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in... | November 10, 2022